

# Michael W Beresford

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4981566/publications.pdf>

Version: 2024-02-01

189  
papers

7,803  
citations

61984

43  
h-index

64796

79  
g-index

195  
all docs

195  
docs citations

195  
times ranked

8544  
citing authors

#	ARTICLE	IF	CITATIONS
1	Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE. <i>Rheumatology</i> , 2023, 62, SI210-SI225.	1.9	9
2	The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2022, , .	0.4	3
3	Prospective epidemiological study of juvenile-onset systemic lupus erythematosus in the UK and Republic of Ireland. <i>Rheumatology</i> , 2022, 61, 4097-4106.	1.9	3
4	Longitudinal analysis of urinary proteins in lupus nephritis – A pilot study. <i>Clinical Immunology</i> , 2022, 236, 108948.	3.2	4
5	Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. <i>Rheumatology</i> , 2022, 61, 3378-3389.	1.9	17
6	What Have We Learnt About the Treatment of Juvenile-Onset Systemic Lupus Erythematosus Since Development of the SHARE Recommendations 2012?. <i>Frontiers in Pediatrics</i> , 2022, 10, 884634.	1.9	4
7	Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. <i>Clinical Immunology</i> , 2022, 239, 109028.	3.2	6
8	A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. <i>Rheumatology</i> , 2021, 60, 3747-3759.	1.9	26
9	Kidney outcomes for children with lupus nephritis. <i>Pediatric Nephrology</i> , 2021, 36, 1377-1385.	1.7	53
10	Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study. <i>Lancet Rheumatology</i> , The, 2021, 3, e111-e121.	3.9	23
11	Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK. <i>Lupus</i> , 2021, 30, 597-607.	1.6	24
12	“It is good to have a target in mind”: qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5630-5641.	1.9	17
13	Behçet’s syndrome in children and young people in the United Kingdom and the Republic of Ireland: a prospective epidemiological study. <i>Rheumatology</i> , 2021, 60, 4728-4736.	1.9	6
14	Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE? – observations from the UK JSLE Cohort Study. <i>Rheumatology</i> , 2021, 60, 5271-5281.	1.9	21
15	Juvenile Idiopathic Arthritis Associated Uveitis. <i>Children</i> , 2021, 8, 646.	1.5	15
16	Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1673-1682.	5.6	17
17	Serum protein signatures differentiate paediatric autoimmune/inflammatory disorders. <i>Clinical Immunology</i> , 2021, 229, 108790.	3.2	4
18	Comment on: Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?: Reply. <i>Rheumatology</i> , 2021, , .	1.9	0

#	ARTICLE	IF	CITATIONS
19	Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. <i>Pediatric Rheumatology</i> , 2021, 19, 135.	2.1	85
20	1675â€¦Real world treatment of juvenile systemic lupus erythematosus (JSLE): evidence from the UK JSLE cohort study. , 2021, , .		0
21	Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. <i>Lupus</i> , 2021, 30, 1955-1965.	1.6	16
22	The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data. <i>Rheumatology</i> , 2020, 59, 1391-1397.	1.9	12
23	Establishing an international awareness day for paediatric rheumatic diseases: reflections from the inaugural World Young Rheumatic Diseases (WORD) Day 2019. <i>Pediatric Rheumatology</i> , 2020, 18, 71.	2.1	1
24	Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. <i>RMD Open</i> , 2020, 6, e001257.	3.8	21
25	Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e217-e226.	3.9	25
26	Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). <i>Clinical Immunology</i> , 2020, 214, 108375.	3.2	19
27	A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. <i>BMC Nephrology</i> , 2020, 21, 245.	1.8	46
28	Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. <i>Lancet Rheumatology, The</i> , 2020, 2, e135-e141.	3.9	62
29	Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. <i>Lancet Rheumatology, The</i> , 2020, 2, e99-e109.	3.9	38
30	Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. <i>Lupus</i> , 2020, 29, 474-481.	1.6	62
31	Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study. <i>Health Technology Assessment</i> , 2020, 24, 1-152.	2.8	3
32	Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. <i>Rheumatology</i> , 2019, 58, 94-102.	1.9	20
33	The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial. <i>EClinicalMedicine</i> , 2019, 12, 79-87.	7.1	24
34	P07â€¦Identifying the primary outcome measure and protocol components for a prospective feasibility study of corticosteroid regimens for CYP with JIA using consensus methods with young people, families and professionals. <i>Rheumatology</i> , 2019, 58, .	1.9	0
35	cAMP Response Element Modulator $\hat{\pm}$ Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus. <i>Journal of Immunology</i> , 2019, 203, 2807-2816.	0.8	21
36	Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. <i>Clinical Immunology</i> , 2019, 209, 108274.	3.2	94

#	ARTICLE	IF	CITATIONS
37	The European network for care of children with paediatric rheumatic diseases: care across borders. <i>Rheumatology</i> , 2019, 58, 1188-1195.	1.9	15
38	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 579-590.	3.4	15
39	Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial. <i>American Journal of Ophthalmology</i> , 2019, 207, 170-174.	3.3	35
40	Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO. <i>PLoS ONE</i> , 2019, 14, e0215739.	2.5	19
41	The human glomerular endothelial cells are potent pro-inflammatory contributors in an in vitro model of lupus nephritis. <i>Scientific Reports</i> , 2019, 9, 8348.	3.3	23
42	Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. <i>Lupus</i> , 2019, 28, 613-620.	1.6	33
43	European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 1607-1616.	1.9	165
44	Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2019, 58, 1453-1458.	1.9	11
45	Working together to deliver stratified medicine research effectively. <i>British Medical Bulletin</i> , 2019, 129, 107-116.	6.9	3
46	Challenges of achieving clinical remission in a national cohort of juvenile-onset systemic lupus erythematosus patients. <i>Lupus</i> , 2019, 28, 667-674.	1.6	7
47	Reply. <i>Ophthalmology</i> , 2019, 126, e24-e25.	5.2	0
48	Mesangial cells are key contributors to the fibrotic damage seen in the lupus nephritis glomerulus. <i>Journal of Inflammation</i> , 2019, 16, 22.	3.4	20
49	A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activity. <i>Clinical Immunology</i> , 2019, 198, 71-78.	3.2	12
50	Ophthalmology research in the UK's National Health Service: the structure and performance of the NIHR's Ophthalmology research portfolio. <i>Eye</i> , 2019, 33, 610-618.	2.1	4
51	Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. <i>Ophthalmology</i> , 2019, 126, 415-424.	5.2	18
52	Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. <i>Rheumatology</i> , 2019, 58, 331-335.	1.9	27
53	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides—the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 656-671.	1.9	77
54	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease—the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 672-682.	1.9	103

#	ARTICLE	IF	CITATIONS
55	Big data and stratified medicine: what does it mean for children?. Archives of Disease in Childhood, 2019, 104, 389-394.	1.9	11
56	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. Journal of Rheumatology, 2019, 46, 190-197.	2.0	318
57	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technology Assessment, 2019, 23, 1-140.	2.8	18
58	American College of Rheumatology Provisional Criteria for Global Flares in Childhood-onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 813-822.	3.4	19
59	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrhumdis-2018-213030.	0.9	183
60	Measuring Disease Damage and Its Severity in Childhood-onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 1621-1629.	3.4	28
61	Child-centred research is the key to progress. Nature Reviews Rheumatology, 2018, 14, 69-70.	8.0	1
62	Neutrophil activation signature in juvenile idiopathic arthritis indicates the presence of low-density granulocytes. Rheumatology, 2018, 57, 488-498.	1.9	30
63	Anti-neutrophil cytoplasmic antibodies and their clinical significance. Clinical Rheumatology, 2018, 37, 875-884.	2.2	37
64	Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology, 2018, 57, 398-401.	1.9	36
65	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.9	9
66	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Annals of the Rheumatic Diseases, 2018, 77, 241-250.	0.9	36
67	Protective parents and permissive children: what qualitative interviews with parents and children can tell us about the feasibility of juvenile idiopathic arthritis trials. Pediatric Rheumatology, 2018, 16, 76.	2.1	6
68	CS-10...Criteria for clinically relevant improvement in children & adolescents with childhood-onset systemic lupus erythematosus. , 2018, , .		0
69	Clinical predictors of active LN development in children – evidence from the UK JSLE Cohort Study. Lupus, 2018, 27, 2020-2028.	1.6	12
70	Growing international evidence for urinary biomarker panels identifying lupus nephritis in children – verification within the South African Paediatric Lupus Cohort. Lupus, 2018, 27, 2190-2199.	1.6	10
71	The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): a systematic review. Lupus, 2018, 27, 2135-2145.	1.6	13
72	Podocytes contribute, and respond, to the inflammatory environment in lupus nephritis. American Journal of Physiology - Renal Physiology, 2018, 315, F1683-F1694.	2.7	24

#	ARTICLE	IF	CITATIONS
73	Clinical predictors of proteinuric remission following an LN flare - evidence from the UK JSLE cohort study. <i>Pediatric Rheumatology</i> , 2018, 16, 14.	2.1	8
74	A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the Tj ETQq0 0 0 ggBT /Overlock 10 Tf 156	1.6	25
75	Urinary biomarkers in childhood lupus nephritis. <i>Clinical Immunology</i> , 2017, 185, 21-31.	3.2	17
76	Optimising the use of medicines to reduce acute kidney injury in children and babies. , 2017, 174, 55-62.		8
77	Inter-observer variability of the histological classification of lupus glomerulonephritis in children. <i>Lupus</i> , 2017, 26, 1205-1211.	1.6	25
78	Oral Ulcers in Juvenile-Onset Systemic Lupus Erythematosus: A Review of the Literature. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 755-762.	6.7	20
79	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1637-1641.	0.9	75
80	Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 1637-1646.	27.0	315
81	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1788-1796.	0.9	139
82	NIHR Clinical Research Networks: what they do and how they help paediatric research. <i>Archives of Disease in Childhood</i> , 2017, 102, 755-759.	1.9	10
83	Evaluation of the ACR and SLICC classification criteria in juvenile-onset systemic lupus erythematosus: a longitudinal analysis. <i>Lupus</i> , 2017, 26, 1285-1290.	1.6	28
84	Do classic blood biomarkers of JSLE identify active lupus nephritis? Evidence from the UK JSLE Cohort Study. <i>Lupus</i> , 2017, 26, 1212-1217.	1.6	5
85	Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , 2017, 102, 206.2-207.	1.9	14
86	Adalimumab for Uveitis in Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2017, 377, 789-790.	27.0	14
87	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1965-1973.	0.9	105
88	Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14
89	Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort. <i>Journal of Autoimmunity</i> , 2017, 84, 55-64.	6.5	121
90	International validation of a urinary biomarker panel for identification of active lupus nephritis in children. <i>Pediatric Nephrology</i> , 2017, 32, 283-295.	1.7	46

#	ARTICLE	IF	CITATIONS
91	Preface: Recent advances in autoimmune and auto-inflammatory diseases in childhood. Best Practice and Research in Clinical Rheumatology, 2017, 31, 439-440.	3.3	0
92	Juvenile-onset systemic lupus erythematosus (JSLE) – Pathophysiological concepts and treatment options. Best Practice and Research in Clinical Rheumatology, 2017, 31, 488-504.	3.3	62
93	Differences in disease phenotype and severity in SLE across age groups. Lupus, 2016, 25, 1542-1550.	1.6	159
94	Differential changes in gene expression in human neutrophils following TNF- $\alpha$ stimulation: Up-regulation of anti-apoptotic proteins and down-regulation of proteins involved in death receptor signaling. Immunity, Inflammation and Disease, 2016, 4, 35-44.	2.7	17
95	Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. Journal of Antimicrobial Chemotherapy, 2016, 71, 3168-3178.	3.0	21
96	Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatric Drugs, 2016, 18, 181-195.	3.1	19
97	Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers. Rheumatology, 2016, 55, 1556-1565.	1.9	38
98	Increased concentration of plasma TNFR1 and TNFR2 in paediatric lupus nephritis. Lupus, 2016, 25, 1040-1044.	1.6	16
99	Increased expression of low density granulocytes in juvenile-onset systemic lupus erythematosus patients correlates with disease activity. Lupus, 2016, 25, 407-411.	1.6	45
100	Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. Trials, 2015, 16, 268.	1.6	17
101	Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study. Arthritis Research and Therapy, 2015, 17, 295.	3.5	30
102	OP3. Developing a urinary biomarker panel for monitoring LUPUS NEPHRITIS disease activity. Rheumatology, 2015, 54, ii3-ii3.	1.9	0
103	PP6. Felty's syndrome in rheumatoid factor positive polyarticular juvenile idiopathic arthritis: the role of rituximab. Rheumatology, 2015, 54, ii7-ii7.	1.9	0
104	PP1. Factors associated with choice of first biologic among children with JIA: a combined analysis from two UK paediatric biologic registers. Rheumatology, 2015, 54, ii5-ii5.	1.9	0
105	274. Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from Two UK Paediatric Biologic Registers. Rheumatology, 2015, , .	1.9	0
106	Co-existence of juvenile-onset systemic lupus erythematosus and juvenile myasthenia gravis. Lupus, 2015, 24, 1462-1463.	1.6	1
107	Characterization of human disease phenotypes associated with mutations in <i>TREX1</i> , <i>RNASEH2A</i> , <i>RNASEH2B</i> , <i>RNASEH2C</i> , <i>SAMHD1</i> , <i>ADAR</i> , and <i>IFIH1</i> . American Journal of Medical Genetics, Part A, 2015, 167, 296-312.	1.2	447
108	Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature. Pediatric Rheumatology, 2015, 13, 1.	2.1	61



#	ARTICLE	IF	CITATIONS
109	The development and assessment of biological treatments for children. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 379-394.	2.4	8
110	Increased soluble phagocytic receptors sMer, sTyro3 and sAxl and reduced phagocytosis in Juvenile-onset Systemic Lupus Erythematosus. <i>Pediatric Rheumatology</i> , 2015, 13, 10.	2.1	39
111	Juvenile-onset systemic lupus erythematosus: how to diagnose and manage. <i>Paediatrics and Child Health (United Kingdom)</i> , 2015, 25, 555-560.	0.4	0
112	The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. <i>Lupus</i> , 2015, 24, 10-17.	1.6	70
113	The protective effect of GM-CSF on serum-induced neutrophil apoptosis in juvenile systemic lupus erythematosus patients. <i>Clinical Rheumatology</i> , 2015, 34, 85-91.	2.2	23
114	Elicitation of Expert Prior Opinion: Application to the MYPAN Trial in Childhood Polyarteritis Nodosa. <i>PLoS ONE</i> , 2015, 10, e0120981.	2.5	32
115	Connective tissue diseases in children. , 2015, , 868-875.		1
116	A Novel Dried Blood Spot-LCMS Method for the Quantification of Methotrexate Polyglutamates as a Potential Marker for Methotrexate Use in Children. <i>PLoS ONE</i> , 2014, 9, e89908.	2.5	33
117	Biologic choices after first-line anti-tumour necrosis factor failure in non-systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , 2014, , .	1.9	0
118	Investigating biomarkers of disease activity in juvenile-onset lupus nephritis. <i>Rheumatology</i> , 2014, , .	1.9	0
119	Investigating phagocytosis receptors in serum from juvenile-onset systemic lupus erythematosus patients. <i>Rheumatology</i> , 2014, , .	1.9	0
120	Improving care in paediatric rheumatic diseases: the SHARE project. <i>Rheumatology</i> , 2014, , .	1.9	0
121	Methodology of clinical trials for rare diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 247-262.	3.3	28
122	A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). <i>Trials</i> , 2014, 15, 14.	1.6	89
123	Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. <i>Nature Genetics</i> , 2014, 46, 503-509.	21.4	490
124	Urine biomarkers for monitoring juvenile lupus nephritis: a prospective longitudinal study. <i>Pediatric Nephrology</i> , 2014, 29, 397-405.	1.7	42
125	The pro-inflammatory potential of T cells in juvenile-onset systemic lupus erythematosus. <i>Pediatric Rheumatology</i> , 2014, 12, 4.	2.1	22
126	Mucocutaneous manifestations in a UK national cohort of juvenile-onset systemic lupus erythematosus patients. <i>Rheumatology</i> , 2014, 53, 1504-1512.	1.9	30



#	ARTICLE	IF	CITATIONS
127	Population Pharmacokinetics of Teicoplanin in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6920-6927.	3.2	29
128	New insights into the pathogenesis and management of lupus in children. <i>Archives of Disease in Childhood</i> , 2014, 99, 563-567.	1.9	27
129	Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. <i>Pediatric Rheumatology</i> , 2014, 12, 31.	2.1	9
130	Predictors of access to care in juvenile systemic lupus erythematosus: evidence from the UK JSLE Cohort Study. <i>Rheumatology</i> , 2014, 53, 557-561.	1.9	11
131	The Medicines for Children Research Network: building on current success as we move forward. <i>Clinical Investigation</i> , 2014, 4, 399-405.	0.0	2
132	Urine biomarkers in juvenile-onset SLE nephritis. <i>Pediatric Nephrology</i> , 2013, 28, 363-374.	1.7	32
133	Paediatric use of mycophenolate mofetil. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 45-59.	2.4	39
134	International Consensus for Provisions of Quality-Driven Care in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2013, 65, 1416-1423.	3.4	53
135	Children and adolescents with SLE: not just little adults. <i>Lupus</i> , 2013, 22, 1309-1319.	1.6	42
136	Adding to complexity: comorbidity in paediatric rheumatic disease. <i>Rheumatology</i> , 2013, 52, 22-33.	1.9	10
137	Protein Kinase C $\delta$ Deficiency Causes Mendelian Systemic Lupus Erythematosus With B Cell-Defective Apoptosis and Hyperproliferation. <i>Arthritis and Rheumatism</i> , 2013, 65, 2161-2171.	6.7	155
138	How to use lupus anticoagulants: Table 1. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2013, 98, 52-57.	0.5	4
139	Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. <i>Rheumatology</i> , 2013, 52, 1941-1951.	1.9	27
140	Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1983-1988.	0.9	126
141	NIHR Medicines for Children Research Network: improving children's health through clinical research. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 581-587.	3.1	17
142	Paediatric-onset systemic lupus erythematosus. , 2013, , .		1
143	Multi-disciplinary care in juvenile-onset systemic lupus erythematosus. <i>British Journal of School Nursing</i> , 2012, 7, 325-330.	0.1	0
144	Standard 5: Selection, Measurement, and Reporting of Outcomes in Clinical Trials in Children. <i>Pediatrics</i> , 2012, 129, S146-S152.	2.1	67

#	ARTICLE	IF	CITATIONS
145	Expression of Toll-like receptors and their detection of nuclear self-antigen leading to immune activation in JSLE. <i>Rheumatology</i> , 2012, 51, 824-832.	1.9	21
146	Increased Serum Concentration of Sphingosine-1-phosphate in Juvenile-onset Systemic Lupus Erythematosus. <i>Journal of Clinical Immunology</i> , 2012, 32, 1019-1025.	3.8	41
147	Juvenile idiopathic arthritis: Managing the condition. <i>British Journal of School Nursing</i> , 2012, 7, 170-174.	0.1	2
148	Inactive disease and remission in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012, 64, 683-693.	3.4	34
149	Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. <i>Arthritis and Rheumatism</i> , 2012, 64, 2356-2365.	6.7	170
150	Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway. <i>PLoS ONE</i> , 2012, 7, e29512.	2.5	41
151	Differential expression of factors involved in the intrinsic and extrinsic apoptotic pathways in juvenile systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 71-79.	1.6	14
152	Juvenile Idiopathic Arthritis. <i>Paediatric Drugs</i> , 2011, 13, 161-173.	3.1	30
153	Diagnosis and management of juvenile-onset SLE. <i>Paediatrics and Child Health (United Kingdom)</i> , 2011, 21, 539-545.	0.4	5
154	Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. <i>Nature Genetics</i> , 2011, 43, 127-131.	21.4	214
155	Needle-free and microneedle drug delivery in children: A case for disease-modifying antirheumatic drugs (DMARDs). <i>International Journal of Pharmaceutics</i> , 2011, 416, 1-11.	5.2	74
156	Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1213-1223.	3.4	28
157	Cellular localization of nuclear antigen during neutrophil apoptosis: mechanism for autoantigen exposure?. <i>Lupus</i> , 2011, 20, 641-646.	1.6	20
158	Communication about Children's Clinical Trials as Observed and Experienced: Qualitative Study of Parents and Practitioners. <i>PLoS ONE</i> , 2011, 6, e21604.	2.5	57
159	Disease modifying immunosuppressant drugs for juvenile-onset systemic lupus erythematosus. <i>The Cochrane Library</i> , 2010, , .	2.8	0
160	A randomized comparative trial of generalized vs targeted physiotherapy in the management of childhood hypermobility. <i>Rheumatology</i> , 2010, 49, 315-325.	1.9	66
161	Comment on: Developing standards of care for patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2010, 49, 2227-2229.	1.9	9
162	A retrospective clinical analysis of pharmacological modalities used for symptomatic relief of Raynaud's phenomenon in children treated in a UK paediatric rheumatology centre. <i>Rheumatology</i> , 2010, 49, 193-194.	1.9	13

#	ARTICLE	IF	CITATIONS
163	New advances in the management of juvenile idiopathic arthritis-2: The era of biologicals. Archives of Disease in Childhood: Education and Practice Edition, 2009, 94, 151-156.	0.5	48
164	New advances in the management of juvenile idiopathic arthritis-1: Non-biological therapy. Archives of Disease in Childhood: Education and Practice Edition, 2009, 94, 144-150.	0.5	23
165	The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 60, 2390-2401.	6.7	77
166	Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology, 2008, 47, 985-990.	1.9	35
167	Improving the evidence base for treatment of juvenile idiopathic arthritis: the challenge and opportunity facing the MCRN/ARC Paediatric Rheumatology Clinical Studies Group. Rheumatology, 2008, 47, 563-566.	1.9	12
168	ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain, 2007, 130, 2045-2054.	7.6	292
169	Acrimonious acronyms: CRMO, SAPHO and a sore shin. Clinical Immunology, 2007, 122, 252-254.	3.2	3
170	So doctor, what exactly is wrong with my muscles? Glutaric aciduria type II presenting in a teenager. Neuromuscular Disorders, 2006, 16, 269-273.	0.6	33
171	So doctor, what exactly is wrong with my muscles? Glutaric aciduria type II presenting in a teenager. Neuromuscular Disorders, 2006, 16, 613.	0.6	2
172	Adolescent development and SLE. Best Practice and Research in Clinical Rheumatology, 2006, 20, 353-368.	3.3	19
173	Twelve-Month Prospective Study of Oxygen Saturation Measurements among Term and Preterm Infants. Journal of Perinatology, 2005, 25, 30-32.	2.0	15
174	Cardio-pulmonary involvement in juvenile systemic lupus erythematosus. Lupus, 2005, 14, 152-158.	1.6	52
175	Does sustained lung inflation at resuscitation reduce lung injury in the preterm infant?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2005, 90, F406-F410.	2.8	83
176	Does the use of 50% oxygen at birth in preterm infants reduce lung injury?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2005, 90, F401-F405.	2.8	44
177	Pamidronate in the treatment of childhood SAPHO syndrome. British Journal of Rheumatology, 2004, 43, 1246-1251.	2.3	99
178	Bronchoalveolar Lavage Surfactant Protein A, B, and D Concentrations in Preterm Infants Ventilated for Respiratory Distress Syndrome Receiving Natural and Synthetic Surfactants. Pediatric Research, 2003, 53, 663-670.	2.3	40
179	Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2002, 87, 62F-63.	2.8	24
180	Detectable IL-8 and IL-10 in Bronchoalveolar Lavage Fluid from Preterm Infants Ventilated for Respiratory Distress Syndrome. Pediatric Research, 2002, 52, 973-978.	2.3	61

#	ARTICLE	IF	CITATIONS
181	Detectable IL-8 and IL-10 in Bronchoalveolar Lavage Fluid from Preterm Infants Ventilated for Respiratory Distress Syndrome. <i>Pediatric Research</i> , 2002, 52, 973-978.	2.3	9
182	Outcome of congenital diaphragmatic hernia. <i>Pediatric Pulmonology</i> , 2000, 30, 249-256.	2.0	88
183	Randomised controlled trial of patient triggered and conventional fast rate ventilation in neonatal respiratory distress syndrome. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2000, 82, F14-F18.	2.8	54
184	Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. <i>Archives of Disease in Childhood</i> , 2000, 83, 313-316.	1.9	73
185	Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. <i>Lancet, The</i> , 2000, 355, 1387-1392.	13.7	110
186	H. C. Darby (ed.): <i>A new historical geography of England</i> . Cambridge: University Press, 1973. 781 pp., 158 figs. £13.00, \$38.50.. <i>Antiquity</i> , 1975, 49, 155-156.	1.0	0
187	Two cases of juvenile systemic lupus erythematosus with uncommon associations and challenges in therapy. <i>Rheumatology</i> , 0, , .	1.9	0
188	Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma. <i>AMRC Open Research</i> , 0, 3, 20.	1.7	2
189	A systematic literature review on diagnosis and treatment of paediatric rheumatic diseases: a shared initiative. <i>Rheumatology</i> , 0, , .	1.9	0